UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,290	03/03/2004	Frank S. D'Amelio SR.	45437	3540
/	7590 09/04/2008 YLANCE, ABRAMS, BERDO & GOODMAN, L.L.P.		EXAMINER	
1300 19TH STREET, N.W.			ROBERTS, LEZAH	
SUITE 600 WASHINGTON,, DC 20036			ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			09/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/791,290	D'AMELIO ET AL.
Office Action Summary	Examiner	Art Unit
	LEZAH W. ROBERTS	1612
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (136(a). In no event, however, may a reply be tirwill apply and will expire SIX (6) MONTHS from (6), cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 11 J This action is FINAL . 2b) ☐ This 3)☐ Since this application is in condition for alloward closed in accordance with the practice under B	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4)	wn from consideration.	lication.
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the drawing(s) be held in abeyance. Set tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority document 3. ☐ Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D: 5) Notice of Informal F 6) Other:	ate

DETAILED ACTION

This Office Action is in response to the Request for Continued Examination filed June 11, 2008. All previous rejections have been withdrawn unless stated below.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims

Claim Rejections - 35 USC § 103 – Obviousness (Previous Rejection)

1) Claims 1, 9 and 11 were rejected under 35 U.S.C. 103(a) as being unpatentable over Romanowski et al (US 2005/0158252). The rejection is maintained.

Applicant's Arguments

Applicants submit that it would not have been obvious to one of ordinary skill in the art in view of Romanowski et al. to combine the claimed ingredients in an amount to inhibit inflammation of oral tissue as in claim 1. The rejection is based on randomly selecting certain components disclosed in Romanowski et al. and the reference provides no guidance or suggestion to combine the components in the claimed manner. Based on the disclosure in Romanowski et al., hundreds of potential compounds and compositions could be prepared by randomly picking and choosing selected components. The rejection relies on Applicants' disclosure to make the selection, and thus, does not establish prima facie obviousness. Furthermore, Applicants have found

Art Unit: 1612

that each of the components show a particular function and provides a specific property to the composition when combined to provide an oral composition to inhibit inflammation. The enhanced performance of the specific combination of the plant components are exhibited by the claimed combination. Applicant further submits the bio-saponin is found to function as a natural surfactant which breaks down the outer layer of cells and other waxy layers, which enables the gota kola to function more effectively to promote lyses of bacteria. Bio-saponin also functions as a foaming agent and enhances the performance of the other components such as the Centipeda extract, coenzyme Q10, aloe vera, folic acid, and Vitamin E. Romanowski et al. clearly does not disclose or suggest these features or the claimed combination of the active components.

Examiner's Response

In regards to holistic extract, Applicant discloses a holistic extract contains a water soluble fraction and an alcohol soluble fraction, yet Applicant does not appear to disclose what ratios or the procedure that is used to obtain the holistic extract of the instant claims. In regards to the combination of components, as asserted before by the Examiner, it is *prima facie* obviousness to select a known material based on its suitability for its intended use and the ingredients in the claims are disclosed by Romanowksi et al. as agents that kill microorganisms, reduce inflammation and rebuild damaged tissue. Therefore it would have been obvious to combine these components

Art Unit: 1612

for their functional value. The suggestion for adding the components together is the recitation that the components may be included into the compositions. Although Applicant has argued that bio-saponin provides the compositions with enhanced activity due to its mechanism of action on the cells, Applicant has not shown any evidence of this action as suggested in the previous office action dated January 11, 2008, page 4. Furthermore Applicant does not recite the effective amount in which bio-saponin is needed to achieve the asserted function (see Remarks, page 11).

2) Claims 1-3, 7, 9, 11-13, 16, 17, 22, 24, 25 and 28-33 were rejected under 35 U.S.C. 103(a) as being unpatentable over Close (US 2002/0044977) in view of Harrison (The Periodontal Solution: Healthy Gums Naturally) and Rice et al. (US 5,741,138). The rejection is maintained.

Applicant's Arguments

Applicant argues the combination of the cited patents and publications as a whole does not disclose or suggest the claimed composition and provide no teaching or suggestion to combine the components in the manner of the claimed invention. Close does not disclose or suggest a holistic extract of *Centipeda cunninghami* as in claim 1 or the extract in combination with the other active components. The combination of the claimed plant materials is not a random selection, but instead, a combination based on

Art Unit: 1612

experimentation to provide the anti-inflammatory properties in the oral composition. The specific combination of components and the amounts of the components provide a moisturizing feel to the mouth compared to the drying or astringent feel of the prior compositions. The art of record provides no teaching or suggestion to combine the components in the claimed amounts or that the claimed components provide the properties of the present invention. The rejection is based on randomly selecting certain components from Close, Harrison and Rice et al. and clearly uses Applicants' disclosure as a guide to select the components and to combine them in the manner that is disclosed only in Applicants' specification. The Action provides no basis for the position that it would have been obvious to select the claimed components from the broad list of components in each of the cited patents to attain the claimed composition.

Examiner's Response

As mentioned above, Applicant discloses a holistic extract contains a water soluble fraction and an alcohol soluble fraction, yet Applicant does not appear to disclose what ratios or the procedure that is used to obtain the holistic extract of the instant claims. Close also discloses the extract is obtained from an aqueous alcoholic extract, therefore encompassing "holistic". The reference also suggests incorporating abrasives, solvents, humectants, detergents, binders, herbal actives (e.g. aloe vera), essential oils (e.g. eucalyptus oil, peppermint oil), deodorizing agents (e.g. chlorophyll) and/or a suspension agents (e.g. hydrogenated castor oil). The secondary reference provides the functional value of components encompassed by these categories, thereby

giving motivation as to why one of ordinary skill in the art would have used these components in conjunction with the compositions of Close. Furthermore it is *prima facie* obviousness to select a known material based on its suitability for its intended use. See MPEP 2144.07, which further supports the instant rejection.

Allowable Subject Matter

Claims 10 and 26 are allowable. The following is a statement of reasons for the indication of allowable subject matter: the claims appear to be allowable over the cited prior art because they provide specific weight percentages for each component. The prior art provides no motivation for combining all the recited components in the recited amounts.

Claims 1-3, 7, 11-13, 16, 17, 22, 24, 25 and 28-33 are rejected.

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH W. ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached on 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick F. Krass can be reached on 571-272-0580. The fax phone

Application/Control Number: 10/791,290 Page 7

Art Unit: 1612

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Lezah W Roberts/ Examiner, Art Unit 1612

/Frederick Krass/ Supervisory Patent Examiner, Art Unit 1612